Searchable abstracts of presentations at key conferences in endocrinology

ea0035p835 | Pituitary Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

AIP expression in non-functioning pituitary adenomas is strongly associated with the gonadotroph phenotype but not with tumour aggressiveness

Rotondi Sandra , Oliva Maria Antonietta , Esposito Vincenzo , Ventura Luca , Giangaspero Felice , Alesse Edoardo , Jaffrain-Rea Marielise

The aryl hydrocarbon receptor interacting protein gene has been mainly involved in the pathogenesis of GH/PRL-secreting pituitary adenomas (PA). We wished to study the significance of AIP expression in clinically non-functioning PA (NFPA).Material and methods: 48 NFPA -27 gonadotroph (GnPA), 21 null cell (ncPA) – were studied for AIP, βFSH and cyclin D1 expression by real-time RT-PCR (qRT), compared with four normal post-mortem pituitaries (NP)...

ea0037ep694 | Pituitary: basic and neuroendocrinology | ECE2015

Single dose irradiation of GH3 cells increase GH and PRL secretion in vitro

Fratticci Amato , Rotondi Sandra , Modarelli Alessio , Bonfili Pierluigi , Cesare Ernesto Di , Alesse Edoardo , Jaffrain-Rea Marie-Lise

Radiotherapy (RT) may represent a useful tool in the treatment of GH-secreting tumours in the presence of a post-operative active disease and single dose stereotactic RT/gamma knife is the preferred option in most cases. The effects of RT on the control of hormone secretion are very slow and pharmacological treatment remains necessary for years. Some authors advocate withdrawal of somatostatin analogues (SSA) during RT, although the short-term effects of RT on hormone secretio...

ea0014p153 | (1) | ECE2007

The beta-HLH transcription factor neurogenin-2 is preferentially expressed by secreting pituitary adenomas

Fratticci Amato , Grieco Fabio , Spilioti Cristina , Giangaspero Felice , Esposito Vincenzo , Santoro Antonio , Ventura Luca , Alesse Edoardo , Jaffrain-Rea Marie-Lise

Beta-HLH transcription factors are involved in the ontogenesis of neural/neuroendocrine cells, and may play a role in the pathogenesis of neuroendocrine tumours. Neurogenin 2 (Ngn2) is expressed by the developing mouse pituitary. After preliminary data indicating its expression in the normal human pituitary, we have studied its phenotypic expression in normal and adenomatous pituitary tissues.Methods: Fifty-two pituitary adenomas (PA) – 23 clinicall...

ea0011p497 | Endocrine tumours and neoplasia | ECE2006

Differential expression of neurogenins by human pituitary adenomas

Fratticci A , Padronetti R , Giangaspero F , Ventura L , Piccirilli M , Esposito V , Gulino A , Alesse E , Jaffrain-Rea ML

The beta-HLH transcription factors NeuroD1 and ASH1 are frequently expressed by pituitary adenomas, both being present in all corticotroph, most clinically non-secreting (CNS) and a subset of GH and/or PRL-secreting adenomas. We wished to investigate the expression of the related beta-HLH factors neurogenins (Ngn) 1, 2 and 3 in the pituitary (n=4) and in a series of pituitary adenomas (n=45). RT-PCR was performed at different amplification cycles (up to 45) in al...

ea0035p834 | Pituitary Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Expression of peroxisome-proliferator activated receptor α in pituitary tumours

Rotondi Sandra , Modarelli Alessio , Rostomyan Lilya , Oliva Maria Antonietta , Esposito Vincenzo , Ventura Luca , Arcella Antonietta , Alesse Edoardo , Beckers Albert , Jaffrain-Rea Marielise

Peroxisome-proliferator activated receptors (PPARs) are involved in a number of neoplasia. PPARα (PPARα) is a partner of the aryl hydrocarbon receptor interacting protein (AIP), which is involved in the pathogenesis of pituitary adenomas (PA). We wished to investigate the potential expression and biological significance of PPARα in PA, especially in GH/PRL-secreting tumours.Material and methods: A large series of PA was collected (n</e...

ea0029p1343 | Pituitary Basic | ICEECE2012

Aryl hydrocarbon receptor interacting protein in somatotroph adenomas: a molecular target for somatostatin analogues?

Jaffrain-Rea M. , Angelini M. , Occhi G. , Turchi A. , Castermans E. , Ceccato F. , Arcella A. , Esposito V. , Giangaspero F. , Pennelli G. , Daly A. , Alesse E. , Scaroni C. , Beckers A.

The aryl hydrocarbon receptor interacting protein (AIP) gene is abundantly expressed in normal somatotrophs. Somatotropinomas in patients with germline AIP mutations (AIPmut) are typically more aggressive than non-AIPmut adenomas and associated with higher GH/IGF1 secretion. AIP downregulation may also occur in sporadic somatotropinomas, especially in invasive tumours. We wished to evaluate the impact of somatostatin analogues (SSA) pre-treatment on AIP expression in sporadic ...

ea0016p454 | Neuroendocrinology | ECE2008

Aryl hydrocarbon receptor interacting protein (AIP) expression in human pituitary adenomas

Jaffrain-Rea Marie-Lise , Spilioti Cristina , Vanbellinghen Jean-Francois , Daly Adrian , Gargano Donatella , D'Innocenzo Emanuela , Giangaspero Felice , Tichomirowa Maria , Esposito Vincenzo , Ventura Luca , Naves Luciana , Alesse Edoardo , Beckers Albert

Background: Germline AIP mutations confer a predisposition to pituitary adenomas (PA), usually in the setting of familial isolated pituitary adenomas (FIPA); AIP mutations account for 50% of familial acromegaly. AIP-related PA are GH, PRL-secreting or non-secreting. Little is known about AIP expression in PA. Although the prevalence is low, identifying AIP mutations in apparently sporadic PA is important for studying at-risk relatives. Pre-screening criteria would help select ...